Xenetic Biosciences (XBIO) AI Stock Analysis

• Market Cap: $7.47M
• Dividend Yield: N/A
• Average Volume (3M): 1.70M
• Price to Earnings (P/E): ―
• Beta (1Y): 0.02
• Revenue Growth: 13.30%
• EPS Growth: 22.70%
• Country: US
• Employees: 2
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): N/A
• Shares Outstanding: 2,291,056
• 10 Day Avg. Volume: 5,053,508
• 30 Day Avg. Volume: 1,695,238
• PEG Ratio: 0.04
• Price to Book (P/B): 0.50
• Price to Sales (P/S): 1.24
• P/FCF Ratio: -1.61
• Enterprise Value/Market Cap: -0.43
• Enterprise Value/Revenue: -1.08
• Enterprise Value/Gross Profit: -1.46
• Enterprise Value/Ebitda: 1.14
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 50 Neutral
• Price Target: $3.50 ▲(58.37% Upside)
• Action: Reiterated Date: 03/17/26
• Date: Action: Reiterated 03/17/26

The score is held down primarily by weak financial fundamentals (ongoing losses and negative free cash flow), partially offset by constructive technical trend strength. Valuation is constrained by unprofitability and no dividend, and the delayed annual meeting adds incremental governance-related risk.

Positive Factors

Debt-light balance sheet

A near-zero debt load is a durable financial advantage for a development-stage biotech. It reduces refinancing and interest burdens, preserves strategic optionality for R&D investment or partnerships, and lowers bankruptcy risk while the company advances clinical programs.

Revenue re-acceleration

Renewed top-line growth indicates improving commercial traction or licensing/activity that supports program progress. Sustained revenue momentum can lengthen runway, attract partners, and validate elements of the business model beyond one-off financing activities.

Improving cash-burn trend

Sequential reductions in cash burn signal improving operational discipline and efficiency. While free cash flow remains negative, a consistent improvement trend lowers near-term funding pressure and makes future capital raises or partnership funding less dilutive.

Negative Factors

Persistent negative cash flow

Chronic negative operating and free cash flow create ongoing dependence on external capital. This structural cash burn forces recurring fundraising, risks dilution, and can constrain the timing and scale of clinical programs or commercialization investments over the medium term.

Sustained large net losses

Material and persistent net losses erode shareholder equity and reflect that the business has not reached operating scale. Negative margins and negative ROE are structural issues that hinder internal capital generation and increase reliance on external financing over multiple years.

Governance / shareholder engagement risk

Repeated adjournments signal weak shareholder engagement and governance friction. This can delay strategic decisions, complicate financings or M&A, and raise investor governance risk—issues that materially affect long-term strategic flexibility and stakeholder confidence.

Xenetic Biosciences Business Overview & Revenue Model

Company Description

Xenetic Biosciences, Inc., a biopharmaceutical company, focuses on advancing XCART, a personalized chimeric antigen receptor T cell (CAR T) platform technology engineered to target patient-specific tumor neoantigens. The company engages in the discovery, research, and development of biologic drugs and oncology therapeutics. It advances cell-based therapeutics targeting the B-cell receptor on the surface of an individual patient's malignant tumor cells for the treatment of B-cell lymphomas. It is also leveraging PolyXen, its proprietary drug delivery platform, by partnering with biotechnology and pharmaceutical companies. It has collaboration agreements with Takeda Pharmaceutical Co. Ltd., Serum Institute of India Limited, PJSC Pharmsynthez, and SynBio LLC. Xenetic Biosciences, Inc. is headquartered in Framingham, Massachusetts.

How the Company Makes Money

null

Xenetic Biosciences Financial Statement Overview

Summary

Improving revenue momentum and a debt-light balance sheet are positives, but the company still has persistent large net losses and recurring negative operating/free cash flow, implying continued reliance on external funding.

Income Statement

Revenue has expanded over time and re-accelerated in 2025 (annual revenue up ~4.1% after a slight decline in 2024), showing improving top-line traction. However, profitability remains weak: the company has posted sizable net losses every year, and while loss margins have narrowed materially versus 2020–2022, 2025 still shows a ~-90% net margin. The earnings profile is still heavily negative, indicating the business has not yet reached sustainable operating scale.

Balance Sheet

The balance sheet is conservatively structured with essentially no debt (debt-to-equity ~0 in recent years), which reduces financial risk and refinancing pressure. Total assets and equity remain positive, but equity has declined meaningfully from 2021–2022 levels, reflecting ongoing losses. Returns on equity are consistently negative, underscoring that shareholder capital is currently being consumed rather than compounded.

Cash Flow

Cash generation remains a key weakness: operating cash flow and free cash flow are negative in every year provided, indicating continued cash burn to fund operations. Cash burn improved in 2024 and again in 2025 versus 2023, but 2025 free cash flow still declined versus 2024 (free cash flow growth ~-15.9%), suggesting volatility in funding needs. Overall, the company remains dependent on external capital to sustain operations.

Breakdown	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	2.98M	2.50M	2.54M	1.71M	1.16M
Gross Profit	0.00	2.50M	2.54M	1.71M	1.16M
EBITDA	-2.83M	-4.05M	-4.52M	-6.69M	-5.71M
Net Income	-2.68M	-3.96M	-4.13M	-6.55M	-5.65M
Balance Sheet
Total Assets	8.36M	6.90M	10.61M	14.72M	19.82M
Cash, Cash Equivalents and Short-Term Investments	7.88M	6.17M	8.98M	13.10M	18.24M
Total Debt	0.00	0.00	0.00	0.00	27.04K
Total Liabilities	968.02K	894.26K	809.59K	1.07M	1.42M
Stockholders Equity	7.40M	6.01M	9.80M	13.65M	18.39M
Cash Flow
Free Cash Flow	-2.29M	-2.82M	-4.11M	-5.15M	-4.74M
Operating Cash Flow	-2.29M	-2.82M	-4.11M	-4.65M	-4.74M
Investing Cash Flow	0.00	0.00	0.00	-500.00K	0.00
Financing Cash Flow	4.00M	0.00	0.00	0.00	11.45M

Xenetic Biosciences Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 2.21
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For XBIO, the sentiment is Positive. The current price of 2.21 is below the 20-day moving average (MA) of 2.59, below the 50-day MA of 2.41, and below the 200-day MA of 3.00, indicating a bullish trend. The MACD of 0.20 indicates Negative momentum. The RSI at 62.54 is Neutral, neither overbought nor oversold. The STOCH value of 68.99 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for XBIO.

Xenetic Biosciences Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
XBIO	50 Neutral	$7.47M	-1.38	-60.33%	―	13.30%	22.70%
VYNE	48 Neutral	$20.99M	-0.94	-74.15%	―	6.29%	7.42%
APRE	47 Neutral	$8.73M	-0.67	-87.05%	―	-62.75%	23.87%
HCWB	43 Neutral	$4.25M	―	275.61%	―	-87.93%	65.26%

Xenetic Biosciences Corporate Events

Xenetic Biosciences faces ongoing delays in annual meeting

On December 11, 2025, Xenetic Biosciences, Inc. announced that its 2025 Annual Meeting of Stockholders, originally scheduled for that day, was adjourned until January 8, 2026 to achieve a quorum and allow more time to solicit proxies on behalf of the board. When the meeting reconvened on January 8, 2026, it was again adjourned without any business conducted due to the continued lack of a requisite quorum, and the company now plans to reconvene the meeting at a future, yet-to-be-determined date, signaling ongoing stockholder engagement and governance challenges that could delay corporate decision-making.

The most recent analyst rating on (XBIO) stock is a Hold with a $2.00 price target. To see the full list of analyst forecasts on Xenetic Biosciences stock, see the XBIO Stock Forecast page.